Pharmacokinetics of BPTU in Melanoma-Bearing Mice
Author Information
Author(s): R. Verrijkl, I.J.H. Smolders, R. Huiskamp, P.R. Gavin, K.H.I. Philipp, A.C. Begg
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Can BPTU effectively target pigmented melanoma cells compared to non-pigmented cells?
Conclusion
BPTU shows better retention in pigmented melanoma tumors than in non-pigmented ones, indicating its potential as a candidate for boron neutron capture therapy.
Supporting Evidence
- BPTU was retained better in pigmented B16 tumors than in non-pigmented variants.
- BPTU demonstrated higher affinity for B16 tumors than BSH.
- Brain boron levels were approximately 10-fold lower than tumor boron levels.
- Multiple dosing of BPTU increased tumor boron concentration significantly.
Takeaway
This study found that a drug called BPTU sticks better to dark melanoma tumors than to light ones, which could help treat skin cancer better.
Methodology
The study involved administering BPTU and BSH to mice with pigmented and non-pigmented tumors and measuring boron levels in various tissues over time.
Limitations
The solubility limits of BPTU restricted the maximum dose that could be administered.
Participant Demographics
C57/BL mice bearing subcutaneous pigmented or non-pigmented B16 melanomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website